Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients Haematologica
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms bioRxiv
Low input capture Hi-C (liCHi-C) identifies promoter-enhancer interactions at high-resolution Nat Commun
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy TRANSPL CELL THER
International consensus on the initial diagnostic workup of cancer of unknown primary CRIT REV ONCOL HEMAT
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis HEMASPHERE
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia BLOOD ADV
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary Future Oncol
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries FRONT MED-LAUSANNE